SecBot SecBot

NGNE

Neurogene Inc.
Nasdaq· Pharmaceutical Preparations· CIK 0001404644 Biotech & Drug Discovery
$23.57 +0.02 (+0.08%)
Oct 26 4:00 PM ET · prev $23.55
Market cap
$485.9M
Small cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
$65.00
+176% · range $46.00–166.00
1 year
−26.5%
from $32.06 · Oct 27
30 days
−17.2%
from $28.48
52-week range
$16.37–42.84
−45% from high · low Feb 5
Avg volume 20D
316.1K
shares / day
Short interest
4.97M
≈24.9% of shares · +51.7%
Days to cover
11.7
at average volume
Insider net
−$1.1M
0 buyers · 4 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/3
Strongest NEUTRAL Prudential Financial Inc. disclosed a passive 11.2% stake in Neurogene Inc. via a Schedule 13G filed on…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • S Feb 27 1 insider sell $120.5K at $25.11
  • S Mar 13 2 insiders sell $225.6K at $20.81
  • S Mar 26 3 insiders sell $147.4K at $21.88
  • S May 6 1 insider sell $300.0K at $31.25
  • S Jul 1 to Jul 7 4 days of insider sells: $340.0K by 1 insider, avg $35.41
  • R Aug 11 Neurogene reported Q2 2026 financial results, highlighting continued…
  • X Sep 30 Short interest jumps 51.7% to 4.97M
  • A Oct 8 JP Morgan initiates

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $1.1M.

  • InstitutionsBULLISH

    Q2 2026: 12 added (0 new), 8 trimmed or exited.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$1.275 → −$1.454 over 90 days. 3 up, 3 down in 30 days.

  • Short sellersBUILDING

    Short interest +51.7% to 4.97M shares. 11.7 days to cover, ≈24.9% of shares.

  • TrendDOWNTREND

    25% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
STATE STREET CORPTRIM224,322$7.1M
MORGAN STANLEYTRIM191,724$6.0M
DRIEHAUS CAPITAL MANAGEMENT LLCDOUBLED143,528$4.5M
VANGUARD PORTFOLIO MANAGEMENT LLCADD95,601$3.0M
MILLENNIUM MANAGEMENT LLCNEAR_EXIT42,734$1.3M
DIMENSIONAL FUND ADVISORS LPDOUBLED32,628$1.0M
AMERICAN CENTURY COMPANIES INCADD23,330$733.7K
RENAISSANCE TECHNOLOGIES LLCTRIM20,405$641.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy6Buy8Hold1Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +176%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 8, 2026JP Morgan
INITIATE
INITIATEOverweight
Aug 12, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Aug 12, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Aug 12, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jun 9, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$1.1M
sold · 4 insiders
DateInsiderTypeValue
Sep 22, 2026
McMinn Rachel
Chief Executive Officer
EXERCISE$19.1K
Jul 7, 2026
Cvijic Christine Mikail
President and CFO
SELL$151.8K
Jul 6, 2026
Cvijic Christine Mikail
President and CFO
SELL$21.6K
Jul 2, 2026
Cvijic Christine Mikail
President and CFO
SELL$87.5K
Jul 2, 2026
Cvijic Christine Mikail
President and CFO
SELL$53.9K
Jul 1, 2026
Cvijic Christine Mikail
President and CFO
SELL$25.2K
May 6, 2026
Cvijic Christine Mikail
President and CFO
SELL$144.4K
May 6, 2026
Cvijic Christine Mikail
President and CFO
SELL$155.7K

Earnings setup

Estimates
−$1.45
EPS estimate, this quarter
−14%
estimate change, 90 days
3↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.45-$1.59–-$1.36-2.4%$0.00
Next Q-$1.43-$1.64–-$1.20-3.8%$0.00
Current FY-$5.75-$6.19–-$5.44-1.6%$0.00
Next FY-$5.72-$7.72–-$4.99-10.6%$0.00

Short side

FINRA· Sep 30, 2026
4,974,749
shares short
+51.7%
vs prior settlement
11.7
days to cover
≈24.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 7, 2026 SEC
Prudential Financial Inc. disclosed a passive 11.2% stake in Neurogene Inc. via a Schedule 13G filed on October 7…
SC 13G — Impact 4/10
Oct 6, 2026 SEC
Jennison Associates LLC disclosed a 5%+ passive stake in Neurogene Inc. via a Schedule 13G filing, reporting…
SC 13G — Impact 4/10
Sep 30, 2026 Short interest report
Short Interest: NGNE up 52% to 5.0M shares
Settlement 2026-09-30 | Days to cover: 11.73 | ≈24.86% of shares outstanding (est.)
Sep 22, 2026 Insider
McMinn Rachel acquired via exercise 756 shares
Chief Executive Officer @ $25.32 ($19.1K)
Aug 11, 2026 SEC
Neurogene reported Q2 2026 financial results, highlighting continued positive Phase 1/2 data for NGN-401 in Rett…
8-K — Impact 7/10
Jul 7, 2026 Insider
Cvijic Christine Mikail sold 4,200 shares
President and CFO @ $36.13 ($151.8K)
Jul 6, 2026 Insider
Cvijic Christine Mikail sold 600 shares
President and CFO @ $36.02 ($21.6K)
Jun 30, 2026 Inst.
STATE STREET CORP — TRIM
224,322 shares ($7.1M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 23, 2026
Earnings date
🔒 Fresh data, subscribers only
Recent
Sep 30, 2026
Short interest
Short Interest: NGNE up 52% to 5.0M shares
Settlement 2026-09-30 | Days to cover: 11.73 | ≈24.86% of shares outstanding (est.)
Aug 7, 2026
Earnings date
NGNE Q2 2026 Earnings Before Market Open — 2026-08-07
May 8, 2026
Earnings date
NGNE Q1 2026 Earnings Before Market Open — 2026-05-08
Apr 16, 2026
Short interest
FTD: NGNE — 48,713 shares ($1.2M) failed to deliver
Settlement: 20260416, Price: $24.00, FTD Value: $1,169,112, NEUROGENE INC COM
Mar 23, 2026
Earnings date
NGNE Q4 2025 Earnings After Market Close — 2026-03-23

SecBot reports

7 filings · 3 bullish · 1 bearish · 1 mixed · 2 neutral
All NGNE filing & press-release reports (7)